Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
topic
Journal for ImmunoTherapy of Cancer
Special collections
JITC
Commentary/Editorials
Email alerts
Commentary/Editorials
Jeffrey S Weber, MD, PhD (1952–2024): in memoriam to discovery, friendship and family
Jason John
Luke
,
Omid
Hamid
,
Bernard A
Fox
,
Paolo A
Ascierto
,
Iman
Osman
,
James J
Mule
,
Pedro J
Romero
,
Michael T
Lotze
Journal for ImmunoTherapy of Cancer
Sep 2024,
12
(9)
e010464;
DOI:
10.1136/jitc-2024-010464
scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC
Qi
Peng
,
Yuanyuan
Xu
,
Xinsheng
Yao
Journal for ImmunoTherapy of Cancer
Sep 2024,
12
(9)
e009376;
DOI:
10.1136/jitc-2024-009376
Immune checkpoint blockade: timing is everything
Frank A
Sinicrope
,
Mary Jo
Turk
Journal for ImmunoTherapy of Cancer
Aug 2024,
12
(8)
e009722;
DOI:
10.1136/jitc-2024-009722
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy
Tomoko
Akaike
,
Austin J
Jabbour
,
Peter H
Goff
,
Song Y
Park
,
Shailender
Bhatia
,
Paul
Nghiem
Journal for ImmunoTherapy of Cancer
Jul 2024,
12
(7)
e009396;
DOI:
10.1136/jitc-2024-009396
Acknowledging and addressing real-world challenges to treating immune-related adverse events
Mitchell S
von Itzstein
,
David E
Gerber
,
Bonnie L
Bermas
,
Alexa
Meara
Journal for ImmunoTherapy of Cancer
Jul 2024,
12
(7)
e009540;
DOI:
10.1136/jitc-2024-009540
Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?
Manar
Elsayed
,
Carrie
Ye
Journal for ImmunoTherapy of Cancer
Jul 2024,
12
(7)
e009309;
DOI:
10.1136/jitc-2024-009309
A crisis in clinical research
David S
Hong
,
Patricia
LoRusso
,
Mario
Sznol
Journal for ImmunoTherapy of Cancer
Jul 2024,
12
(7)
e008520;
DOI:
10.1136/jitc-2023-008520
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines
Jeffrey
Schlom
,
Renee N
Donahue
,
Claudia
Palena
,
Sofia R
Gameiro
,
James W
Hodge
,
Duane H
Hamilton
,
James L
Gulley
Journal for ImmunoTherapy of Cancer
Jul 2024,
12
(7)
e009595;
DOI:
10.1136/jitc-2024-009595
Perspectives from the leadership of
Journal for ImmunoTherapy of Cancer
Sjoerd H
van der Burg
,
Michael T
Lotze
Journal for ImmunoTherapy of Cancer
Jun 2024,
12
(6)
e009661;
DOI:
10.1136/jitc-2024-009661
Hypothesis: AdAPT-001 and pseudoprogression – when seeing is not necessarily believing
Anthony
Conley
,
Christopher
Larson
,
Bryan
Oronsky
,
Meaghan
Stirn
,
Scott
Caroen
,
Tony R
Reid
Journal for ImmunoTherapy of Cancer
Jun 2024,
12
(6)
e008809;
DOI:
10.1136/jitc-2024-008809
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »
Special collections
COVID-19
(45)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(567)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(993)
Commentary/Editorials
(154)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(56)
Guidelines and Consensus Statements
(53)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(248)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(441)
Liquid Biopsies
(10)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(151)
Reviews
(245)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(5055)
Press releases
(3)
